High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients. 1991

H J Coppens, and C J Slooff, and A M Paans, and T Wiegman, and W Vaalburg, and J Korf
Department of Clinical Psychiatry, Groningen University, The Netherlands.

We investigated whether the lack of therapeutic response to long-term and adequate neuroleptic treatment was due to a failure to achieve a blockade of cerebral dopamine receptors. Six chronic schizophrenic and medicated patients (DSM-III-R diagnosis, paranoid or disorganized type) were assessed with the Present State Examination and the Brief Psychiatric Rating Scale. According to the Chouinard Rating Scale there were little extrapyramidal symptoms, although no anticholinergic drugs were given. Plasma levels of the neuroleptics were determined and found in the therapeutic range or higher. Dopamine D2-receptor occupancy was determined with positron emission tomography using 11C-methylspiperone as ligand. There was a more than 95% blockade of the D2 receptors in the striatum. These results indicate that the lack of therapeutic response and extra-pyramidal side effects cannot be attributed to an incomplete blockade of cerebral D2 receptors and that the pathogenetic role of these receptors can be questioned in therapy-resistant schizophrenic patients.

UI MeSH Term Description Entries
D008297 Male Males
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D011954 Receptors, Dopamine Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells. Dopamine Receptors,Dopamine Receptor,Receptor, Dopamine
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder
D012565 Schizophrenic Psychology Study of mental processes and behavior of schizophrenics. Psychology, Schizophrenic

Related Publications

H J Coppens, and C J Slooff, and A M Paans, and T Wiegman, and W Vaalburg, and J Korf
February 1994, Archives of general psychiatry,
H J Coppens, and C J Slooff, and A M Paans, and T Wiegman, and W Vaalburg, and J Korf
January 1988, Archives of general psychiatry,
H J Coppens, and C J Slooff, and A M Paans, and T Wiegman, and W Vaalburg, and J Korf
February 2019, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
H J Coppens, and C J Slooff, and A M Paans, and T Wiegman, and W Vaalburg, and J Korf
March 1998, Archives of general psychiatry,
H J Coppens, and C J Slooff, and A M Paans, and T Wiegman, and W Vaalburg, and J Korf
May 2010, Psychopharmacology,
H J Coppens, and C J Slooff, and A M Paans, and T Wiegman, and W Vaalburg, and J Korf
January 1996, European journal of pharmacology,
H J Coppens, and C J Slooff, and A M Paans, and T Wiegman, and W Vaalburg, and J Korf
January 1993, European journal of clinical pharmacology,
H J Coppens, and C J Slooff, and A M Paans, and T Wiegman, and W Vaalburg, and J Korf
January 1990, The American journal of psychiatry,
H J Coppens, and C J Slooff, and A M Paans, and T Wiegman, and W Vaalburg, and J Korf
April 1989, The British journal of psychiatry : the journal of mental science,
H J Coppens, and C J Slooff, and A M Paans, and T Wiegman, and W Vaalburg, and J Korf
September 1995, International clinical psychopharmacology,
Copied contents to your clipboard!